Search results
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Added:
1 year ago
Original Research
Lipoprotein(a): A Risk Factor and Biomarker in Heart Failure
Added:
1 month ago
Review Article
Added:
3 weeks ago
HFA Congress 2026 — Dr Ida Arentz Taraldsen (Amager and Hvidovre Hospital, Copenhagen University Hospital, Hvidovre, DK) discusses REDOX-AHF, a prospective, randomised, blinded, multicentre pilot trial evaluating restrictive versus liberal oxygenation targets in patients hospitalised with acute heart failure and pulmonary congestion.Although oxygen therapy is widely used in the acute management…
View more
Added:
3 weeks ago
HFA Congress 2026 — Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) joins us to discuss findings from the UF-CARE trial, evaluating ultrafiltration against enhanced medical therapy in patients with type 2 cardiorenal syndrome.This randomised, open-label study enrolled patients with severe, refractory heart failure and concurrent chronic kidney disease, a population with a high…
View more
Added:
3 weeks ago
HFA Congress 2026 — Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) joins us to discuss findings on diuretic resistance drawn from TRANSFORM-HF, a large-scale, pragmatic, randomised clinical effectiveness trial comparing torsemide versus furosemide in patients hospitalised with heart failure.TRANSFORM-HF enrolled 2,973 patients across 60 US sites, randomising 1:1…
View more
Added:
3 weeks ago
HFA Congress 2026 — Dr David Žižek (University Medical Centre Ljubljana, Ljubljana, SI) joins us to discuss findings from CONDUCT-AF, a randomised, multicentre trial comparing conduction system pacing (CSP) with biventricular (BiV) pacing following atrioventricular node ablation (AVNA) in heart failure patients with symptomatic atrial fibrillation and narrow QRS.The trial enrolled 82 patients…
View more
Added:
2 weeks ago
HFA Congress 2026 — SUBCUT-HF II: subcutaneous furosemide for early supported discharge in worsening heart failure. Dr Ross Campbell (University of Glasgow, UK) shares results from SUBCUT-HF II, a multicentre, phase 2, randomised controlled trial evaluating subcutaneous furosemide in patients hospitalised with worsening heart failure.A total of 172 patients across 22 UK centres were randomised to…
View more
Added:
2 months ago
ACC.26 - Dr Anuradha Lala-Trindade (Mount Sinai, New York, NY, US) provides her expert analysis of the most impactful late-breaking clinical trials presented at ACC.26, highlighting studies with the potential to influence clinical practice and shape future cardiovascular care. Key Late-Breaking Trials Discussed0:16 – STEMI-DTU: Primary Left Ventricular Unloading in Anterior ST-Segment Elevation…
View more
Added:
2 months ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
2 years ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary…
View more